FINWIRES · TerminalLIVE
FINWIRES

Netflix Set to Beat 2026 Guidance Amid Early US Price Increases, UBS Says

-- Netflix (NFLX) may outperform its own guidance for the full year as the impact of earlier-than-expected price increases takes hold, UBS Securities said in a note emailed Thursday.

Last month, the company increased prices across its US plans, including raising its ad-supported standard tier to $8.99 per month from $7.99. The price of its standard plan without ads rose by $2 to $19.99 a month, while the premium tier now costs $26.99, compared with $24.99 previously.

These price increases offer upside potential for 2026 estimates, UBS analysts including John Hodulik wrote.

UBS projects currency neutral revenue growth of 14% with a 32.6% margin rate for 2026, compared with guidance that called for a 11% to 13% revenue increase and a 31.5% margin.

BofA Securities previously said that Netflix's most recent round of price increases highlighted the streaming giant's pricing power.

The company is likely to roll out more hikes in other major markets that are expected to boost average revenue per member, according to the UBS note.

The widening price gap between plans with and without ads, along with new demand-side platform relations with companies including Amazon (AMZN), will likely double Netflix's ad-supported revenue in 2026, Hodulik said.

"While Netflix continues to slowly grow share of total TV viewing in the US, its share of streaming viewership remains under pressure given growth in (free ad-supported television)," Hodulik added.

In February, Netflix dropped its plans to acquire Warner Bros. Discovery (WBD), which will now be acquired by Paramount Skydance (PSKY).

"With the Warner Bros bid behind it, we believe Netflix is still positioned to benefit from its solid slate of content this year including the return of four of its top 20 series, new films such as War Machine and The Rip, a growing list of live events and the ramp in video games," Hodulik said.

Shares of Netflix were up 2.5% in recent trading on Thursday.

Price: $101.64, Change: $+2.25, Percent Change: +2.26%

相关文章

Australia

主要加密货币下跌;比特币跌破75000美元

周二,主流加密货币普遍下跌,其中比特币(BTC-USD)跌破75,000美元关口。 追踪包括比特币在内的数十种数字资产的CoinDesk市场指数在过去24小时内下跌近0.6%。纳斯达克100指数下跌0.5%,标普500指数和道琼斯工业平均指数均下跌约0.6%。 根据CoinMarketCap的数据,比特币下跌1.7%至74,985美元。这种最受欢迎的加密货币的24小时交易量下降7.1%至371亿美元。 市值排名第二的数字资产以太坊(ETH-USD)下跌1.4%至2,297美元。 瑞波币(XRP-USD)下跌1%,币安币(BNB-USD)下跌0.7%,索拉纳币(SOL-USD)下跌1.6%。狗狗币 (DOGE-USD) 下跌 1.6%,卡尔达诺 (ADA-USD) 也下跌 1.6%。 美国 10 年期国债收益率于周二下午 3 点(美东时间)报 4.289%,高于周一的 4.248%;5 年期国债收益率则从 3.848% 升至 3.906%。 过去 24 小时内,加密货币行业总市值下跌 0.6% 至 2.55 万亿美元,交易量下降 1.5% 至 1533.7 亿美元。Price: $74991.13, Change: $-863.67, Percent Change: -1.14%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD
Sectors

行业动态:金融股午后回落

周二下午晚些时候,金融股普遍下跌,纽约证券交易所金融指数下跌0.6%,道富金融精选行业SPDR ETF(XLF)下跌0.3%。 费城住房指数上涨0.8%,道富房地产精选行业SPDR ETF(XLRE)下跌1.6%。 比特币(BTC-USD)下跌0.2%至75,717美元,10年期美国国债收益率上涨4.2个基点至4.29%。 经济方面,美国3月份零售销售额增长1.7%,高于彭博社调查预期的1.4%,也高于上月修正后的0.7%的增幅。剔除机动车销售和加油站销售额15.5%的激增后,3月份零售销售额增长0.6%,与2月份持平。 美国全国房地产经纪人协会的数据显示,尽管抵押贷款利率上升,但3月份美国待售房屋数量仍超出预期。 企业新闻方面,据彭博社报道,摩根大通(JPM)正努力获得中国证券监管机构的批准,计划首次在中国推出主动管理型交易所交易基金(ETF)。摩根大通股价下跌1.3%。 据路透社报道,纽约州总检察长莱蒂西亚·詹姆斯(Letitia James)已对Coinbase(COIN)和Gemini Titan提起诉讼,指控其预测市场涉嫌违反纽约州禁止非法赌博的法律。路透社援引曼哈顿州法院提交的诉状称,Coinbase股价下跌超过7%。 华盛顿信托银行(WASH)周一晚间公布,其第一季度营收同比下降,且低于分析师预期。其股价暴跌近17%。 据彭博社报道,巴克莱银行(BCS)正因其使用重大风险转移(SRT)交易而受到英国监管机构的审查。报道称,此次审查(即《监管法》第166条调查)是由英国审慎监管局(PRA,英格兰银行的监管机构)要求进行的。巴克莱银行股价下跌2.9%。

$BCS$COIN$JPM$WASH
Sectors

板块动态:医疗保健股午后走软

周二下午晚些时候,医疗保健类股下跌,纽约证券交易所医疗保健指数下跌1%,道富医疗保健精选行业SPDR ETF (XLV)下跌0.9%。 iShares生物科技ETF (IBB)下跌1%。 公司新闻方面,美国监管机构告知Passage Bio (PASG),其实验性疗法PBFT02需要进行一项随机对照试验才能获得批准,此举将增加时间、成本和不确定性,令该公司面临更加艰难的处境。Wedbush周二在一份报告中指出,Wedbush将Passage Bio的股票评级从“跑赢大盘”下调至“中性”,并将目标价从32美元下调至8美元。Passage Bio股价下跌2.9%。 默克(MRK)和日本医疗保健公司卫材(Eisai)周二表示,两款药物组合的3期临床试验未能达到主要终点,即无进展生存期和总生存期,作为晚期透明细胞肾细胞癌的一线治疗方案,其疗效与Keytruda联合Lenvima相比逊于后者。默克股价下跌3.7%。 联合健康集团(UNH)周二上调了全年盈利预期,此前这家健康保险巨头公布的第一季度业绩意外实现年度增长。其股价应声上涨超过7%。 奎斯特诊断公司(DGX)公布第一季度调整后盈利和净收入均有所增长,并上调了2026年业绩预期,受此消息提振,其股价上涨超过4%。

$DGX$MRK$PASG$UNH